TSXV:RX - Post Discussion
Biosyent Inc
> BioSyent Extension of RepaGyn® and Proktis-M® Agreement
Post by
Betteryear2 on Apr 15, 2024 6:25pm
BioSyent Extension of RepaGyn® and Proktis-M® Agreement
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. BioSyent Announces Extension of RepaGyn® and Proktis-M® (globenewswire.com)
Be the first to comment on this post